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Abstract 
Introduction: The increased prevalence of Type 2 diabetes mellitus (T2DM) in 
severe mental illness (SMI) contributes to increased cardiovascular morbidity and 
reduced life expectancy for people with SMI.  
Areas covered: In the present clinical review, we summarize the efficacy, safety and 
tolerability of selected diabetic pharmacotherapy options in SMI and discuss the 
quality and strength of evidence.  
Expert commentary: General principles for treating T2DM in SMI involve identifying 
treatments which promote weight loss and which have low or no risk of 
hypoglycemia. Patient engagement in decision making about treatment choices is an 
important factor to ensure adherence and successful use of the chosen therapy. The 
first line therapeutic option for T2DM in SMI for which there is most evidence is 
metformin. Based on general population data, second line treatment options in 
combination with metformin to achieve glycated haemoglobin treatment goals include 
GLP-1R agonists, DPP-4 inhibitors, sulphonylureas, SGLT2 inhibitors, pioglitazone 
and insulin, with most evidence for the use of GLP-1R agonists in SMI. Alongside 
efficacy and tolerability, treatment for T2DM in SMI should be considered on a 
patient-tailored basis. 











Severe mental illnesses (SMIs) are associated with increased rates of cardiovascular 
disease and associated excess premature death [1,2], which translates to a 15 to 20 
year shortened life expectancy for those with SMIs compared to the general 
population [3,4]. Higher rates of modifiable cardiovascular risk factors are seen in 
SMI, with 33-57% of patients with SMI (i.e. schizophrenia, schizoaffective disorder, 
bipolar affective disorder) meeting the criteria for metabolic syndrome throughout the 
course of the illness [5-7].  
Most antipsychotics have the potential to cause weight gain, and increase the risk of 
type 2 diabetes mellitus (T2DM) [8]. Clozapine and olanzapine, which have the 
greatest affinity for 5-HT2C and Histamine (H)1 receptors[9], have the greatest 
weight gain potential, which can occur early in the course of treatment [10-12], before 
plateauing as treatment continues[13]. The most dramatic weight gain is seen in 
antipsychotic naïve patients over the first six weeks of treatment and the majority of 
those with initial weight gain do not lose that weight thereafter, even on switching to 
more weight neutral antipsychotics [10]. Second generation antipsychotics (SGAs) 
such as aripiprazole, amisulpride, lurasidone and asenapine, have a more neutral 
metabolic side effect profile [10,14,15]. 
People with schizophrenia and their families have a higher risk of T2DM than the 
general population, indicative of a genetic liability [16-19]. A comparative meta-
analysis established that people with SMI (n=133,470) are significantly more likely to 
have T2DM than matched controls (n=5,622,664; relative risk=1.85; 95%CI=1.45-
2.37) [14]. T2DM prevalence is consistently elevated in each of the three major 
diagnostic subgroups (schizophrenia, schizoaffective disorder and bipolar affective 
disorder) compared to matched controls [14], especially in males (RR=1.43; 95% 
CI=1.20 to 1.69, p<0.001).   Antipsychotic medication (please see table 1), in 
particular certain SGAs, duration of antipsychotic use and polypharmacy all 
contribute to a heightened risk of T2DM [14,20,21]. Clozapine, in particular, has a 
rapid effect with 55% developing glucose dysregulation within 3 months of starting, 
independent of weight gain [22]. There is preclinical evidence of olanzapine having 
acute, direct effects on glucose homeostasis, with rapid onset of glucose intolerance 
and increased insulin resistance, which can be reversed by antidiabetic medications 
[23]. Meta-analysis of atypical antipsychotic trials in healthy volunteers provides 
evidence of decreased insulin sensitivity and associated increased insulin resistance 
occurring independent of SMI, and as a direct and early consequence of atypical 
antipsychotics[24]. For people with SMI who have an increased endogenous risk for 
glucose dysregulation, this is further exacerbated with the use of antipsychotic 
medication[25].   
Four percent of patients with first episode psychosis (FEP) have T2DM, with rates of 
2.9% seen in antipsychotic naïve FEP patients and 11% in established multi-episode 
psychotic disorders [14]. In a multi-episode psychosis cohort, 20% met criteria for 
T2DM, with a further 30% having evidence of glucose dysregulation [7]. In the meta-
analysis of Vancampfort et al, all individual antipsychotics, except for aripiprazole 
and amisulpride, had significantly higher T2DM risk compared to antipsychotic-naïve 
participants [14].  
Lifestyle factors such as increased prevalence of cigarette smoking[7,26], high levels 
of sedentary behaviour and physical inactivity [27-30], poor diet [31] and suboptimal 
vitamin D levels[32-34] in psychotic disorders further increase the risk of T2DM, 
cardiovascular disease and premature mortality [35,36]. Antipsychotic naïve patients 
have elevated levels of insulin resistance and hypertriglyceridaemia, prior to the use 
of antipsychotic medication [37,38], indicating that people with psychotic disorders 
carry an inherent increased risk for T2DM which is further exacerbated by the 
interplay with other risk factors.  However, a recent GWAS study with Mendelian 
randomisation found no evidence of a causal relationship between schizophrenia and 
diabetes, indicating that lifestyle and environmental changes may be key [39]. The 
study findings adds to inconclusive GWAS findings in diabetes and schizophrenia[40] 
and contrasts with gene association studies identifying several shared genes 
between both disorder[41-43]. The inconsistency between epidemiological data and 
gene association studies which have indicated a shared genetic risk between T2DM 
and schizophrenia, and inconclusive GWAS findings will require additional research 
to account for the discrepancy.   
 
INSERT table 1 here 
 Patients on long term antipsychotics should receive regular monitoring of 
cardiometabolic parameters and evidenced based interventions for glucose 
dysregulation as well as for dyslipidemia and hypertension. However, studies 
continue to demonstrate the suboptimal use of pharmacotherapy for T2DM in SMI. 
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study 
identified that 30% of patients with schizophrenia and T2DM were not receiving 
treatment for T2DM[44]. A later cross sectional study found that only 60% of those 
with schizophrenia and T2DM received diabetic pharmacotherapy [45]. In a UK 
National Audit of 5091 people with SMI, only 53.5% were in receipt of treatment 
(defined in the broadest sense, advise on diet and exercise or prescription for 
diabetic medication) for “high glucose levels”[46]. The UK National Audit of 
Schizophrenia identified in a review of mental health case records that only 36% of 
patients with evidence of glucose dysregulation had received a lifestyle intervention 
or diabetic medication  [47].  
Given the cardiometabolic side effect burden, there is a need for awareness that all 
patients treated with antipsychotics require screening and monitoring for 
cardiometabolic risk, including T2DM and that they may benefit from both 
pharmacological and non-pharmacological interventions for weight loss. Prevention 
and pharmacotherapeutic interventions for T2DM is an important aspect of the 
treatment of psychotic disorders.  
 
2. Aims 
In this present clinical review, we aim to summarise the published efficacy and 
tolerability of pharmacotherapeutic interventions in T2DM in SMI, focusing on 
glucose lowering therapies. The use of other methods for glucose lowering such as 
antipsychotic switching and lifestyle modification [48,49] have been previously 
reviewed and will not be covered in our review 
 
3. Management of type 2 diabetes mellitus (T2DM)  
3.1 Treatment goals  
Glycated haemoglobin, (HbA1c) offers the utility to assess, diagnose and monitor 
T2DM in patients with established SMI, negating the need for a fasting plasma 
sample, although fasting samples are preferred on initiation of antipsychotics 
because of the risk of an idiosyncratic rapid dysregulation of glucose metabolism[22]. 
Generally, the goal for diabetic therapy is to lower glucose levels to attain an HbA1c 
of <7.0% (48mmol/mol) [50,51] with no complications and a relatively long life 
expectancy.  The use of less stringent HbA1c targets may be required for example in 
the elderly patient with significant cardiovascular morbidity, where hypoglycaemia 
may result in significant morbidity. Also, for the patient who does not adhere to the 
diabetic treatment regimen, where non-compliance with clinical care occurs- a strict 
HbA1c target may not be appropriate, it may be difficult to attain with standard 
approaches, and flexibility in defining HbA1c target thresholds is required. This is the 
status for some with SMI and a diagnosis of T2DM. The diagnostic criteria for T2DM 
are shown in box 1.  
 
 
3.2 Treatment algorithms (see Figure 1) 
If a person meets criteria for T2DM but with a HbA1c close within the target range 
(<7.0%), then lifestyle modification, with dietary and exercise advice is 
recommended, with a view to rechecking HbA1c in 3-6 months, before considering 
the need for diabetes pharmacotherapy [52,53].  A recent meta-analysis 
Box 1: Laboratory diagnosis of diabetes  
A diagnosis of diabetes can be made on the basis of any of the following 
laboratory values 
• Fasting blood glucose (on two separate days) ≥7 mmol/L (126 mg/dl)   
• Random plasma glucose ≥ 11·1 mmol/L (200 mg/dl) + Symptoms 
• Haemoglobin A1c≥6·5% (48mmol/mol)  
• Oral glucose tolerance test ≥2 h plasma glucose ≥11·1 mmol/L (200 mg/dL)  
 
demonstrated that lifestyle interventions are effective in improving glycaemic control 
in people with diabetes and SMI[48]. 
The first line pharmacological intervention is to treat with metformin monotherapy in 
addition to lifestyle modification. If HbA1c concentrations are poorly controlled for 3 
months or longer, despite treatment with a single drug (usually considered to be a 
rise of HbA1c to 58 mmol/mol (7.5 %) or higher), drug treatment should be 
intensified, alongside reinforcement of advice regarding diet, lifestyle, and adherence 
to drug treatment. 
For first line treatment with metformin, a target HbA1c concentration of 6.5 % 
(48 mmol/mol) is recommended by some T2DM treatment guidelines in SMI [54]. 
This mirrors general population guidelines [53,55]. However, it is important to 
consider target HbA1c levels at the patient level, and adjust as appropriate to less 
stringent thresholds, such as 7.0% (53mmol/mol) for those with significant 
comorbidities or who are at heightened risk of hypoglycaemia and complications from 
same [50]. For patients with SMI, who may have increased difficulties in applying and 
adhering with diabetes self-management, and appropriate glucose monitoring, then a 
sensible recommendation would be to follow the target HbA1c threshold <7.0% 
(53mmol/mol) as recommended by the American Diabetes Association (ADA) [50]. 
3.3 Optimising glycaemic control 
In the general population second line therapy recommendations involve the 
combination of metformin with a Dipeptidyl peptidase-4 (DPP-4) inhibitor, metformin 
and a sulfonylurea, metformin and a Sodium glucose transporter 2 (SGLT2) inhibitor, 
metformin and a glucagon-like peptide-1 receptor (GLP1R)-agonist, or metformin and 
insulin, with ongoing support of the patient to aim for an HbA1c level of < 7.0% 
(53mmol/mol). Please see figure 1. 
For combination /second line therapy, an HbA1c concentration target of 53 mmol/mol 
(7.0 %) is recommended. However, if this degree of glycaemic control is deemed to 
be inappropriate in a person with SMI, due to concerns regarding hypoglycaemia, 
then following multidisciplinary team discussion and consideration of capacity issues, 
a less stringent HbA1c threshold may be chosen. Less stringent HbA1c goals (such 
as <8% (64 mmol/mol)) may be appropriate for patients with a history of severe 
hypoglycemia, extensive comorbid conditions, or diabetes where the goal is difficult 
to achieve due to patient difficulties in applying and adhering with diabetes self-
management, appropriate glucose monitoring, and effective doses of multiple 
glucose-lowering agent.  
Insert figure 1 here adapted from Inzucchi et al 2015 [56] 
4. Treatment of type 2 diabetes mellitus in severe mental illness 
4.1 Pharmacotherapy for T2DM in SMI 
The overriding emphasis is that people with SMI and comorbid T2DM should be 
managed in line with diabetes treatment guidelines used in the general population, 
as set forth by the ADA [50], International Diabetes Federation[57], American 
association of clinical endocrinologists [55] and the National Institute of Clinical 
Excellence [53]. The comprehensive care required to prevent microvascular and 
macrovascular complications of diabetes requires a combination of lifestyle 
interventions, education programs and pharmacological treatments delivered across 
the healthcare spectrum ranging from the individual, and his or her family to primary 
and secondary care delivery services. In this review we will discuss selected 
treatment strategies for glycemic control in T2DM in SMI. We will focus on 
pharmacological treatments used to manage T2DM in the general population, most 
of which have little trial exposure in SMI populations.  Support for this approach is 
emphasized in a recent meta-analysis of 10 studies reporting data from 33,910 
people with schizophrenia and T2DM which found that people with schizophrenia 
adhered to diabetic medication on 77.3% of days prescribed (n=32080, 95%CI=73.6-
81%, I2=99.2%,), and adhered on 4.6% more days per year than those without 
schizophrenia (p<0.01, 95%CI=2.4-6.7%, I2=92.5%, schizophrenia n=19367, 
controls=170,853) [58].  
4.2 Meta-analysis of treatment of T2DM in SMI 
A recent meta-analysis of the clinical effectiveness of pharmacological (and non-
pharmacological interventions) for improving glycaemic control in people with SMI 
identified that pharmacological  interventions (mean difference (MD), -0.11mmol/L; 
95% confidence interval (CI), [-0.19, -0.02], p = 0.02, n = 2536) were effective in 
lowering fasting glucose, but not HbA1c (pharmacological MD, -0.03%; 95% CI, [-
0.12, 0.06], p = 0.52, n = 1515 compared with usual care or placebo[48]. In a 
subgroup analysis, only sufficient studies to assess the effectiveness of metformin 
and antipsychotic switching were available, with both strategies found to improve 
HbA1c (metformin: MD = -0.08; 95% CI, [-0.14, -0.03]; p = 0.004; I2 = 0% 
;antipsychotic switching: MD = -0.11%; 95% CI, [-0.18, -0.05]; p = 0.001; I2 = 0%), 
and metformin alone: MD = -0.15mmol/L; 95% CI, [-0.29, -0.01]; p = 0.04; I2 = 51% ) 
and with metformin alone improving fasting glucose levels(MD = -0.15mmol/L; 95% 
CI, [-0.29, -0.01]; p = 0.04; I2 = 51%), compared to placebo or control, though with 
modest effect sizes [48]. This replicated previous meta-analysis supporting the 
effectiveness of metformin in improving glycaemic control in SMI, with statistically 
significant improvements in fasting glucose for metformin (MD = -0.18mmol/L; 95% 
CI, [-0.35, 0.00]; n = 9 studies; I2 = 73%); and in HbA1c (MD = -0.08%; 95% CI, [-
0.13, -0.03]; n = 3 studies; I2 = 0%)[59]. This meta-analysis also identified 
improvements in HbA1c with adjunctive aripiprazole (MD = -0.65%; 95% CI, [-1.25, -
0.06]; n = 2 studies; I2 = 89%). Both reviews identified only modest improvements in 
reported HbA1c and fasting glucose with individual pharmacological interventions. 
4.3 Antidiabetic medication selection in SMI 
General principles for treating T2DM in SMI involve identifying treatments which 
promote weight loss and which have low or no risk of hypoglycemia. Patient 
engagement in decision making about treatment choices is important to help with 
adherence and the success of the chosen therapy.  
Obesity is common in people with SMI, with rates of 50% identified, and 83% with 
central obesity (327/396), with a particular high rate in females ( 95% (160/169)) [7], 
so choosing medications which aid weight loss or are weight neutral is preferable. 
These include metformin, incretins such as glucagon-like peptide-1 receptor (GLP-
1R) agonists, dipeptidyl peptidase 4 (DPP4) inhibitors, and sodium-glucose 
cotransporter 2 (SGLT2) agents [52,60]. Sulfonylureas, thiazolidinediones and insulin 
based therapies are associated with increased weight gain [60] compared to other 
diabetic pharmacotherapies, and logically, although not subjected to meta-analysis, 
may not be ideal choices for early use in this population.  
In SMI, the selection of medications should also be guided by risk for hypoglycaemia. 
For people with psychotic illnesses, several factors place them at increased risk of 
complications due to hypoglycaemia. The interplay of active psychotic symptoms, 
cognitive deficits, mood episodes and social factors all may increase the risk to the 
person if hypoglycaemic episodes were to occur, or may reduce their ability to 
identify early hypoglycaemic signs. Hence, agents with a low risk for hypoglycaemia 
such as GLP-1R agonists, DPP-4 inhibitors and the newest SGLT2 inhibitors are 
preferred choices for second line therapies in SMI. Sulfonylureas and insulin are 
associated with an increased risk of hypoglycaemia, and increased need for more 
frequent glucose monitoring, potentially reducing utility and acceptability.  
5. Diabetic medications 
The recommended doses of diabetic medication are shown in table 2. 





Metformin is a biguanide which increases insulin sensitivity, reduces hepatic 
synthesis and release of glucose, and increases glucose uptake by muscles. 
Metformin reduces both basal and post prandial glucose levels. Metformin is 
recommended as the first line treatment for T2DM in all national and international 
guidelines.   
Metformin is generally well tolerated. If persistent hyperglycaemia, metformin may be 
titrated over 2-3 weeks to reduce the risk of nausea and vomiting (affecting 
approximately 10-20%). If poorly tolerated, then the long acting formulation may be 
considered to reduce the occurrence of nausea and vomiting, though this is rarely 
used in clinical practice. Metformin is typically commenced at 500 mg bd and titrated 
every 8-12 weeks to a dose of 1000mg twice daily, based on glycaemic control. 
Periods of 2 months [50] and 3-6 months[53] have been recommended to assess the 
effect of metformin in improving glycaemic control . Please see table 2 for 
recommended medication doses in T2DM. 
In those at risk of diabetes in the general population, a meta-analysis showed that 
metformin was associated with a 40% reduction in the risk of developing T2DM over 
a mean follow up period of 1.8 years [61].  In T2DM in the general population, 
metformin use is associated with lower risk for cardiovascular mortality compared 
with sulfonylureas [60].  
 
5.2 Adverse events 
Metformin was first introduced into clinical practice in Europe in the 1950s, but only 
obtained a licence for use in USA in 1995. Historically, the use of metformin was 
somewhat limited due to concerns regarding the development of lactic acidosis, 
though recent evidence from a systematic review of observational studies has shown 
that the risk is not increased with metformin use in those with mild or moderate renal 
impairment, compared to those with T2DM and not treated with metformin [62]. 
Metformin is contraindicated in those with severe renal impairment (estimated 
glomerular filtration rate <30 ml/min/1.73m2 ), hepatic failure and heart failure due to 
the risk of lactic acidosis. For SMI patients with mild (eGFR 45-59 ml/min/1.73m2  ) or 
moderate (eGFR 30-44 ml/min/1.73m2 ) renal impairment , a more gradual dose 
titration and possible use of a lower maximum dose might increase safety in these 
patients [62]  A baseline renal function assessment is recommended, and 6 monthly 
or annual renal function measures can be taken with cardiometabolic blood markers. 
The long-term use of metformin has been associated with 2.45 increased odds ratio 
of developing vitamin B12 deficiency compared to non-metformin treated 
comparators [63].  Vitamin B12 deficiency secondary to metformin use is associated 
with neuropathy [64], and should be treated with supplementation.   
5.3 Metformin in SMI 
Metformin should be considered as the first line treatment for T2DM in SMI, as it is 
well tolerated, inexpensive and HbA1c reductions of 1% to 2% can be expected with 
monotherapy [50]. In perhaps the best designed study of metformin use to treat 
T2DM in SMI, a double blind study of 148 overweight (BMI ≥27kg/m2) people with 
SMI showed that metformin titrated to 1000mg daily was associated with mild mean 
reduction in HbA1c levels (-0.07%; 95% CI=-0.14 to -0.004), and a mean reduction in 
weight of -2.0 kg (95% CI=-3.4 to -0.6) compared to placebo over a 16 week trial 
period [65]. 
Additionally, metformin has been shown to attenuate weight gain in antipsychotic 
treated patients [59,65-68], with an approximate weight loss of 3kg compared to 
placebo [54].  In T2DM in the general population, metformin has been shown to 
reduce the transition from pre diabetes (defined as a fasting plasma glucose (FPG) 
level of 5.5–6.9 mmol/l or an HbA1c level of 6.0-6.4% (42– 47 mmol/mol) [69]) to 
T2DM [70,71]. Metformin is used in clinical practice to delay or prevent the 
progression to T2DM in those with pre diabetes and SMI (especially in those treated 
with clozapine and olanzapine, both antipsychotics with an increased risk of glucose 
dysregulation)-though as of yet, this recommendation is based on trial data in the 
general population [69,70]. There is no placebo controlled trial data of metformin use 
in SMI to prevent or delay the onset of T2DM in patients with pre diabetes.  
5.4 Combination therapies 
For those who fail to have adequate glycaemic control with metformin, the next step 
in SMI may be the use of either incretin-based therapy glucagon-like peptide 1 
receptor (GLP1-R) agonists or dipeptidyl peptidase 4 (DPP4) inhibitors, 
sulphonylureas or sodium glucose transporter 2 (SGLT2) inhibition agents. The 
approach to consider GLP-1R agonists as a second line diabetic treatment is 
recommended by the American Association of Clinical Endocrinologists in the 
general population [72].  
5.5 Incretins 
These include injectable GLP1-R agonists and DPP4 inhibitors. GLP1-R agonists 
increase glucose-dependent insulin secretion and have a low risk of hypoglycemia, 
and are associated with weight loss. GLP is a gut produced incretin hormone which 
is secreted in response to food intake [73]. It stimulates the release of insulin, 
reduces glucagon release and delays gastric emptying. DPP4 is an enzyme which 
breaks down GLP, thus limiting its action[73]. 
5.6 GLP-1R agonists 
GLP-1R agonists (exenatide, liraglutide, lixisenatide, albiglutide, and dulaglutide) act 
by increasing insulin secretion in response to glucose loads, decreasing glucagon 
secretion and delaying gastric emptying and increasing satiety. The GLP-1R agonists 
are administered as subcutaneous injections and are available in short acting or 
extend release formulations (e.g. Exenatide weekly administration), potentially 
improving adherence and patient acceptability[74]. Exenatide exists in two 
formulations: twice daily (Byetta®) and once weekly (Bydureon®, Eli Lilly and 
Company, Indianapolis, Indiana, USA). Liraglutide (Victoza®, Novo Nordisk A/S, 
Bagsvaerd, Denmark) is administered once daily. Dulaglutide (Trulicity®) is 
administered as a once weekly subcutaneous injection.   
GLP-1R agonists are recommended as second line therapies in the general 
population by the American Diabetes Association (ADA) [50] and the American 
Association of Clinical Endocrinologists [55,72] . In the UK, they are recommended to 
be “used in patients with a BMI ≥ 35 kg/m2 and with specific psychological or medical 
problems associated with obesity; or for those who have a BMI lower than 
35 kg/m2 but for whom insulin therapy would have significant occupational 
implications or if the weight loss associated with glucagon-like peptide-1 receptor 
agonists would benefit other significant obesity-related comorbidities”[75,76]. This 
specific restriction on their use relates to the higher costs, and cost effectiveness of 
GLP-1R agonists compared to other antidiabetic agents[76]. This analysis was based 
on their being more cost effective in comparison with insulin glargine in patients with 
BMI > 33 or 35 kg/m2 , wherein they have an association with a higher degree of 
weight loss compared to insulin[77,78].   In SMI, this needs to be weighed against 
their ability to improve glycaemic control, with little risk of hypoglycaemia, and to 
reduce weight. Further, their administration technique and dose scheduling may 
improve adherence and acceptability, making them applicable for consideration in 
SMI as second line treatments.  
5.7 GLP-1R agonists, administration and benefits in SMI 
The potential for weight loss (average weight loss of 3 to 4.5 kg) and low risk of 
hypoglycaemia seen in general population samples with the use of GLP-1R agonists 
such as exenatide and liraglutide make them attractive options for the treatment of 
T2DM in SMI[73,79-81].  
Exenatide is administered twice daily within one hour of morning and evening meals, 
while the extended release formulation is administered once weekly (2mg dose 
weekly). Liraglutide is administered subcutaneously once daily, and due to its 
intermediate half-life and delayed time to effect compared to exenatide, can be 
administered at any time. Liraglutide and exenatide are associated with mean 
reductions in HbA1c of 0.8%-1.8% [79,82-86]. Extended release exenatide is a once 
weekly subcutaneous injection, and has been associated with mean reductions in 
HbA1c of 1.0%-1.8%[86]. In comparator studies, extended release exenatide has 
been associated with significantly increased reductions in mean HbA1c compared to 
immediate release twice daily exenatide and once daily liraglutide [86,87]. Exenatide, 
luraglutide and other GLP-1R agonists are associated with weight loss[88]. 
Liraglutide has demonstrated dose dependent reductions in body weight, 6.0% (6.4 
kg) with liraglutide (3.0-mg dose), 4.7% (5.0 kg) with liraglutide (1.8-mg dose), and 
2.0% (2.2 kg) with placebo (estimated difference for liraglutide [3.0 mg] vs placebo, -
4.00% [95% CI, -5.10% to -2.90%]; liraglutide [1.8 mg] vs placebo, -2.71% [95% CI, -
4.00% to -1.42%]; P < .001 for both), though with increased gastrointestinal side 
effects with the 3.0mg dose compared 1.8mg and placebo[89]. 
Dulaglutide is administered as a weekly subcutaneous injection at 0.75 mg 
(recommended dose as monotherapy) or 1.5 mg (as an add-on therapy). It is the 
third once weekly GLP-1R formulation, providing improvements in HbA1c of  0.7% to 
1.5%, with 55%–78% of patients attaining HbA1c≤7% and weight loss of 1.3-3.0kg 
[90]. Dulaglutide monotherapy was more efficacious than metformin in attaining 
improved glycaemic control (mean difference in HbA1c: Dulaglutide 1.5mg vs 
metformin -0.22% (-2.4 mmol/mol) and Dulaglutide 0.75mg vs metformin--0.15% (-
1.6 mmol/mol) (p < 0.025, both comparisons))[91]. Dulaglutide in combination with 
metformin (0.75mg and 1.5mg weekly) has demonstrated increased efficacy in 
reducing HbA1c compared to sitagliptin combined with metformin at one year follow 
up (mean HbA1c changes: Dulaglutide 1.5mg: -1.10 +/- 0.06% (-12.0 +/- 0.7 
mmol/mol), Dulaglutide 0.75mg: -0.87 +/- 0.06% (9.5 +/- 0.7 mmol/mol), and 
Sitagliptin: -0.39 +/- 0.06% (4.3 +/- 0.7 mmol/mol) (p < 0.001, both comparisons), 
with greater weight loss for both doses too in comparison with sitagliptin (dulaglutide 
1.5 mg (-3.03 +/- 0.22 kg),  dulaglutide 0.75 mg (-2.60 +/- 0.23 kg) compared with 
sitagliptin (-1.53 +/- 0.22 kg) (p < 0.001, both comparisons) [92]. Dulaglutide has 
shown to lead to greater reductions in HbA1c (1.5mg: -1.51 ± 0.06% (-16.5 ± 0.7 
mmol/mol),0.75mg: -1.30 ± 0.06% (-14.2 ± 0.7 mmol/mol), compared to exenatide 10 
μg ( -0.99 ± 0.06% (-10.8 ± 0.7 mmol/mol)  and placebo -0.46 ± 0.08% (-5.0 ± 0.9 
mmol/mol) (p<0.001) (all treatments in combination with metformin or pioglitazone), 
at 52 weeks, with lower incidence hypoglycaemia in patients receiving dulaglutide 1.5 
mg than in those receiving exenatide [93]. In the AWARD-6 study, at 26 weeks of 
treatment with liraglutide and dulaglutide there was no significant difference in 
reductions in HbA1c between the medications [83].  
5.8 Adverse events with GLP-1R agonists 
They can be associated with nausea and vomiting (in 10-20% of patients) which can 
last for up to 3 months after initiation [73]  and patients should be informed of this 
side effect. The weight loss effects, and reduced cardiovascular mortality associated 
with some agents in this class (liraglutide) [94,95] make them attractive options for 
the treatment of T2DM in SMI. Exenatide requires a dose reduction in severe renal 
impairment, and though no dose change is required for liraglutide and other GLP-1R 
agonists, they should be used with caution and with close monitoring of renal 
function [96,97]. 
The GLP-1R agonists and DPP4 inhibitors have been reported to be associated with 
the occurrence of pancreatitis in a small number of patients in clinical trials and post 
marketing data. However, the results are far from conclusive, with a large meta-
analysis of over 1.3 million people finding that observational data does not support 
the link between GLP-1R agonists and DPP4 inhibitors and pancreatitis [98].  There 
have been mixed reports of associations between exenatide and liraglutide use and 
pancreatic cancer, though analysis of data  by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) indicated that there was 
insufficient evidence to suggest a causal association between incretin therapies and 
pancreatic cancer (or pancreatitis)[99]. Animal studies have identified a potential 
increased risk of thyroid C-cell neoplasms with GLP1 receptor agonists [100], though 
no association has been identified in trial data [89,101]. The use of GLP1 receptor 
agonists is contraindicated in those with a personal or family history of medullary 
thyroid carcinomas or multiple endocrine neoplasia syndrome type 2 [75]. 
5.9 Evidence base for the use of GLP-1R agonists in SMI 
GLP-1R agonists were first shown to reduce clozapine induced weight gain and 
improve glycaemic control in a schizophrenia patient in a 2013 case report [102].Two 
randomised controlled trials( RCTs) have published findings on the use of GLP-1R 
agonists for antipsychotic-associated obesity and glucose tolerance in obese, non-
diabetic patients[103,104], and there is one RCT investigating GLP-1R agonists in 
clozapine-treated patients with either diabetes or obesity[105,106]. 
The first RCT of antipsychotic-treated, obese, non-diabetic, schizophrenia spectrum 
patients, comparing once-weekly subcutaneous exenatide 2mg (n = 23) or placebo 
(n = 22) injections for 3 months identified significant weight loss in both groups [104]. 
However, there was no significant difference in weight loss between the exenatide 
(2.24 +/-3.3kg) and placebo groups (2.23+/- 4.4 kg) after 3 months of treatment 
[104]. This was a naturalistic study cohort of a small number of people with SMIs who 
were treated with a wide range of antipsychotic medications and some with 
antipsychotic polypharmacy. The study authors hypothesise that as antipsychotic 
medications all have dopamine 2 antagonism as a common pharmacodynamic 
effect, that the weight reducing effects of GLP-1R agonists may be related to 
dopaminergic signalling, and thus raising the possibility that the benefits of exenatide 
in SMI may be better matched to patients treated with antipsychotics with relatively 
low dopaminergic affinity (eg quetiapine, olanzapine or clozapine) [104].  
A recent Danish randomized clinical double-blind trial of 214 overweight or obese 
people with a schizophrenia spectrum disorder treated with olanzapine or clozapine 
investigated the use of liraglutide to improve cardiometabolic parameters over a 16 
week period[103]. The trial findings for 103 people randomized to once-daily 
subcutaneous injection of liraglutide (upward titration from 0.6mg to 1.8mg 
(maintenance dose) daily) or placebo, demonstrated compelling evidence to support 
the efficacy of liraglutide versus placebo in improving glucose levels (HbA1c−0.2 
(0.04)% vs 0.06 (0.04)%; ), reducing prediabetic status (−n=13 (85.7%  of liraglutide 
treated patients with pre-existing prediabetes) vs  −6 (40.0% of placebo treated 
patients, ) body weight (decreased by −5.3 kg; 95% CI, −7.0 to −3.7 kg) and low 
density lipoprotein (LDL) (−15.4 mg/dL; 95% CI, −23.2 to −7.7 mg/dL)[103]. This 
important study provides fresh impetus to consider the use of GLP-1R agonists as a 
second line treatment for T2DM in SMI, and potentially as a weight loss agent and in 
preventing the transition from prediabetes to T2DM in those treated with clozapine or 
olanzapine. 
A smaller randomised, controlled, open-label, pilot trial of 28 clozapine treated 
patients were treated with once weekly extended release exenatide 2mg or treatment 
as usual. Compared to usual care those treated with once weekly exenatide had 
significant reductions in mean weight (-5.29kg vs -1.12kg, p=0.015), BMI (-1.78 vs -
0.39 p=0.019), and fasting glucose (-0.34 vs 0.39, p=0.036) and HbA1c (-0.21 vs 
0.03, p=0.004) [106].  These early promising findings in SMI will require further trial, 
and prospective observational data for confirmation and to address the evidence gap 
on their efficacy, tolerability and acceptability to people with SMI.  
No trials of the use of dulaglutide in SMI have yet been conducted, though its once 
weekly administration and efficacy in improving glycaemic control and aiding weight 
loss make it a further attractive option for use in SMI.  
5.10 Dipeptidyl peptidase 4 inhibitors 
Dipeptidyl peptidase 4 inhibitors (e.g. alogliptin, linagliptin, sitagliptin, saxagliptin, and 
vildagliptin,) maintain endogenous GLP1 concentrations, promoting lower glucose 
levels, by preventing the DPP4 enzymatic breakdown of GLP[107]. DPP-4 inhibitors 
have a low risk of hypoglycaemia and are weight neutral. They can be administered 
once daily, simplifying a patient’s medication regimen. They are generally well 
tolerated and are not associated with gastrointestinal side effects [56].  
Trial data with DPP-4 inhibitors in SMI is lacking to date, and efficacy data is 
extrapolated from general population study data. When combined with metformin 
they have been associated with reductions in HbA1c of 0.4%-0.8% [108-111].Dose 
reduction is recommended for DPP4 inhibitors in moderate to severe renal 
impairment, with the exception of linagliptin for which no dose change is required 
[97]. Saxagliptin has been associated with increased risk of hospitalisation due to 
heart failure compared to placebo [112], with the risk clustered in the first year of 
follow up, but not thereafter [113]. Subsequent observational studies have not found 
evidence of an increased risk of hospitalization for heart failure with DPP-4 inhibitors, 
including saxagliptin [114,115].  
5.11 Sulphonylureas  
The use of sulphonylureas is based on trial data in general population samples with 
T2DM, as trial data is lacking in SMI. Previously, the next step to optimise glycaemic 
control after an inadequate response to metformin, would be the addition of a 
sulfonylurea (gliclazide (most commonly used in clinical practice), glibenclamide, 
glimepiride, glipizide, tolbutamide) to metformin. However, this approach while still 
valid in terms of effectiveness in reducing fasting glucose levels, may not a preferred 
option in SMI, due to the risk of hypoglycaemia and weight gain with sulphonylureas 
[60]. Sulphonylureas as monotherapy and in combination with metformin are 
associated with an increased risk of hypoglycaemia, though for the non-obese 
patient with SMI, and with awareness of the risk of hypoglycaemia and diabetes self-
monitoring, they may still be considered. 
5.12 Sodium glucose transporter 2 (SGLT-2) inhibitors  
SGLT-2 inhibitors (e.g. canagliflozin, dapagliflozin, and empagliflozin) are the newest 
diabetic medications. SGLT-2 inhibitors act via a relatively novel insulin independent 
mechanism, though inhibition of SGLT2 receptors in the proximal renal tubules to 
reduce glucose reabsorption by sodium glucose transporter 2 receptors, preventing 
reabsorption of glucose, and promoting glycosuria. This results in reduction of serum 
glucose, without the risk of hypoglycaemia [116]. SGLT-2 inhibitors have been 
associated with average reductions of HbA1C of 0.6%-0.9%[116] and weight loss of 
approximately 2-3kg in T2DM [117,118]. Empagliflozin reduces the risk of heart 
failure and improves cardiovascular outcomes [119]. The most frequent adverse 
effects with SGLT-2 inhibitors relate to their actions in the kidneys and to glycosuria, 
including polyuria, volume depletion with postural hypotension, and urinary and 
genital tract infections [60,117,120].There have been no trial or implementation 
studies of SGLT-2 inhibitors in SMI. 
5.13 Insulin therapy 
For those who have sustained HbA1c levels of > 9% (75 mmol/mol) despite 
combination therapy, the use of insulin can be considered. Basal insulin can be 
combined with oral antidiabetic medications (metformin, sulphonylureas, GLP-1R 
agonists and SGLT-2 inhibitors ). Insulin may be administered as a once a day long 
acting formulation, twice a day mixed insulin or as a basal bolus regimen. This allows 
for enhanced glycaemic control. 
In combination with oral antidiabetic medications in the general population, insulin 
has shown effectiveness in glycaemic control with a low risk of hypoglycaemia.  
Basal insulin is recommended to be commenced at a low dose at night time (e.g. 10 
units) and titrated as per glucose control, generally aiming for 30-50 units to achieve 
target glucose levels and HbA1c. 
Those with significantly elevated HbA1c (>10% (86 mmol/mol)), severe 
hyperglycaemia (>16.7 mmol/L ( 300 mg/dL) or clinical symptoms may be candidates 
for immediate insulin therapy (with or without additional medications) [50]. For those 
who fail to gain a HbA1c < 9.0% (75 mmol/mol), consideration of the use of  insulin 
may be a more effective option, though its use needs to be balanced against the risk 
of hypoglycaemia.  
As complexity increases with increased insulin dosing frequency, the risk of 
complications increases and careful selection of patients which would achieve 
significant benefit over risk is required. Insulin maintenance treatment in patients with 
SMI with sustained elevations of HbA1c despite combination therapy should only be 
selected if patient education allows for patients to understand the treatment, and for 
those with a record of medication adherence who can adhere to the treatment and 
medical follow up. 
5.14 Thiazolidinediones  
Thiazolidinediones (e.g. Pioglitazone, Rosiglitazone) work to improve insulin 
effectiveness by increasing insulin sensitivity and regulating glucose metabolism. 
Trial data for the use of rosiglitazone exists in antipsychotic treated patients with 
schizophrenia.  Double blind trial data supporting reductions in glucose levels in 
patients treated with olanzapine and rosiglitazone (4-8 mg daily) compared to 
placebo and in those treated with rosiglitazone[121]. Non-significant reductions in 
insulin sensitivity index (SI- increases in ‘net fractional glucose clearance rate per 
unit change in serum insulin concentration after an intravenous glucose load’[122]) 
and glucose utilization (SG- the net fractional glucose clearance rate secondary to 
increased glucose independent of increase in circulating insulin concentrations) in 
clozapine patients with insulin resistance, treated with rosiglitazone (4mg daily) 
compared to placebo [122]. These findings suggested that rosiglitazone improved 
insulin sensitivity and glucose utilization in clozapine treated patients, perhaps 
mediated by rosiglitazone’s direct and indirect effects on glucose transporter activity 
[123]. Subsequent to these trials, rosiglitazone was withdrawn from the UK market in 
2010, due to increased risk of myocardial infarction. Pioglitazone is still available as 
an antidiabetic medication.  However, due to concerns regarding the risk of 
cardiovascular disease and heart failure with their use [60], along with their 
propensity to cause weight gain, they are not preferred choices in SMI.  
6. Expert commentary 
There are a number of general principles involved in the pharmacotherapeutic 
management of T2DM in SMI which include: defining a glucose level or HbA1c goal, 
using metformin as first line treatment, the use of combination treatments if required 
to achieve HbA1c goals, the use of agents which may promote weight loss (GLP-1R 
agonists) or are weight neutral (DPP-4 inhibitors or SGLT2 inhibitors) and which 
avoid the occurrence of hypoglycaemic episodes [124]. 
Emerging evidence from pivotal RCTs for the treatment of diabetes in the general 
population report a significant risk reduction in cardiovascular morbidity and mortality 
for patients treated with SGLT-2 inhibitors [119] and GLP-1R agonists [95]. There is 
a critical clinical need to determine the therapeutic benefit of these medications in 
people with SMI and incipient or established diabetes mellitus, and to assess the 
impact on cardiovascular disease risk reduction in SMI.  
When choosing an antidiabetic medication to use both efficacy and tolerability are 
important, not only because adverse effects can reduce subjective well-being and 
adherence, but also because they can adversely affect treatment outcomes. 
Notwithstanding the fact that differences in efficacy among antidiabetic medications 
are relatively small, the need to tailor treatment choice to individual patients is key, 
and shared treatment decisions should be a cornerstone in the management of 
T2DM in SMI. The use of strategies which may increase individual patient adherence 
is recommended. The use of once weekly exenatide or dulaglutide could be 
administered by community mental health nurses, and incorporated into weekly 
patient scheduled contacts or patients could be educated to self-administer the 
injection.  The NICE guideline restrictions for the use of GLP-1R agonists in the UK 
based on cost effectiveness analysis[76], are not mirrored in other international 
guidelines[72]. Further, the restriction for their use in people with a BMI > >35 kg/m2   
is not fully merited based on the key trial data for the use of exenatide and liraglutide 
in which people had mean BMIs of 34.0 kg/m2 and 31.9 kg/m2  [125]respectively, and 
in basing their use on weight loss effectiveness rather than glycaemic efficacy, 
thereby limiting their use in people with refractory T2DM[126]. 
In this clinical review, we have summarised the available evidence and provided a 
clear rationale to guide treatment of T2DM in SMI, along with a treatment algorithm 
for the use of antidiabetic medication in SMI, extrapolated from data derived from 
studies of people with diabetes in general population study samples.  
7. Five-year view 
Trial data in relation to the use of antidiabetic medications (except for metformin) in 
SMI is limited. Prospective observational and implementation studies, and RCTs in 
the use of metformin in combination with GLP-1R agonists, DPP-4 inhibitors, 
sulphonylureas, pioglitazone and SGLT2 inhibitors are needed to address the 
evidence gap on the efficacy, tolerability and acceptability of antidiabetic medications 
in people with SMI. 
While a lack of screening for, and identification of T2DM remains a problem in SMI, 
the major concern is the lack of treatment implementation for T2DM when it is 
identified, and the suboptimal treatment of T2DM, which should be rectified with the 
appropriate implementation of pharmacotherapeutic interventions. The 
comprehensive care required to prevent microvascular and macrovascular 
complications of diabetes will require a combination of lifestyle interventions, 
education programs and pharmacological treatments delivered across the healthcare 
spectrum with the involvement of the patient, their family members and collaborative 
approaches from primary and secondary care (mental health and endocrinology) 
services. Meta-analysis has shown that 56% of people with schizophrenia (n=33680) 
are "adherent" to diabetes medication, which was significantly higher than those 
without schizophrenia, indicating that diabetic medication programs can be 
successfully implemented in this population [58]. We believe that future clinical trials 
that investigate treatment efficacy and switching strategies in T2DM patients in SMI 
will increase our knowledge, familiarity and confidence in using these agents and 
lead to increased treatment implementation for T2DM in this population. 
 8. Conclusion 
In summary, metformin is the recommended first line treatment for T2DM in SMI, with 
emerging data in SMI to support the use of GLP-1R agonists.  The use of DPP-4 
inhibitors, sulphonylureas and SGLT2 inhibitors in combination with metformin to 
achieve HbA1C treatment goals are recommended approaches, but trial data in SMI 
is lacking. 
A patient tailored approach to the selection of antidiabetic medications is required 
regarding the comparative effects and tolerability of treatments and patient 
preference. In ensuring this approach, a diagnosis of SMI or active psychotic 
symptoms should not be an obstacle to the initiation of diabetes medication in this 
patient population. The implementation of treatment protocols for T2DM in SMI and 
studies of their effectiveness and long term clinical outcomes are required. However, 
the paucity of trial data should not impede the appropriate initiation of treatments for 




• There is increasing evidence that people with severe mental illness (SMI) 
have considerably worse physical health than the general population 
• Type 2 diabetes mellitus (T2DM) is more common in people with severe 
mental illnesses with up to 20% meeting criteria for T2DM, and 30% having 
evidence of glucose dysregulation  
• People with SMI and comorbid T2DM receive suboptimal treatment for 
diabetes 
• Treatment with metformin is of proven benefit in this population and is the first 
line medication for the treatment of T2DM in SMI 
• Metformin, and GLP1R- agonists are the only currently available diabetic 
medications investigated in trials of people with SMI and T2DM studies 
• In the management of hyperglycaemia in patients with SMI and T2DM, 
glucagon-like peptide-1 receptor (GLP1R)-agonist, dipeptidyl peptidase-4 
(DPP-4) inhibitor, sulfonylureas, sodium glucose transporter 2 (SGLT2) 
inhibitors, pioglitazone and insulin may be considered as combination therapy 
with metformin if the HbA1c target is not achieved after 3 months of 
metformin monotherapy at maximum tolerated doses 
• Agents with a low risk for hypoglycaemia and which may mediate weight loss, 
such as GLP-1R agonists, DPP-4 inhibitors and the newest SGLT2 inhibitors 
are preferred choices for second line therapies in SMI. 
• Patient engagement in decision making about treatment choices is important 
to help with adherence and the success of the chosen therapy.  
• GLP1-R agonists, exenatide, liraglutide and dulaglutide are associated with 
improved glycaemic control and weight loss. 
• Exenatide and liraglutide have shown improvements in glycaemic control in 
SMI, with liraglutide showing evidence for preventing the transition from 
prediabetes to T2DM in olanzapine and clozapine treated patients 
• Exenatide and dulaglutide are available as once weekly subcutaneous 
injections, potentially improving adherence and acceptability  
• Consider the use of GLP-1R agonists as a second line treatment for T2DM in 
SMI, and potentially as a weight loss agent and in preventing the transition 
from prediabetes to T2DM 
• The major concern remains the lack of appropriate treatment intervention for 
T2DM, and the suboptimal treatment of T2DM in SMI. 
• A relevant question is if earlier treatment with metformin or other agents 
during prediabetes might be beneficial in preventing the transition to T2DM in 
SMI. 
• Prospective observational and implementation studies, and in the use of 
metformin in combination with GLP-1R agonists, DPP-4 inhibitors, 
sulphonylureas, pioglitazone and SGLT2 inhibitors are needed to address the 
evidence gap on the efficacy, tolerability and acceptability of diabetic 
medications in people with SMI. 
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                           Figure 1. Suggested Algorithm for Management of Hyperglycaemia in patients with Diabetes and SMI 
Monotherapy  
Lifestyle (Diet and Exercise) 
Metformin Initially 500 mg BD, Increase to 1000 mg BD, 
↓ 
If not achieving target HbA1c after 3-6 months, Add Second Agent 
Dual Therapy~ 
Normal Weight* 




BMI > 30 
Underweight* 
BMI < 18.5 
Osmotic Symptoms* 
DPP4i GLP-1RA GLP-1RA Sulphonylurea Insulin 
Sulphonulurea SGLT2i SGLT2i DPP4i Sulphonylurea 
TZD DPP4i DPP4i Insulin  
SGLT2i   TZD  
Lifestyle (Diet and Exercise) 
↓ 
If not achieving target HbA1c after 3-6 months, Add Third Agent 
Triple Therapy~ 
Normal Weight* Overweight Obese Underweight* Osmotic Symptoms* 
DPP4i GLP-1RA** GLP-1RA** Sulphonylurea Insulin 
Sulphonylurea*** SGLT2i SGLT2i DPP4i Sulphonylurea 
TZD*** DPP4i** DPP4i** Insulin  
Insulin*** TZD*** TZD*** TZD  
SGLT2i Sulphonylurea*** Sulphonylurea***   
 Insulin*** Insulin***   
Lifestyle (Diet and Exercise) 
↓ 




Basal Bolus Insulin 
Consider GLP-1RA  
*If HbA1c > 10% (86 mmol/mol) or blood glucose > 300 mg/dl (16.6 mmol/L) and significant osmotic  symptoms of polyuria, polydipsia and 
weight loss, assess for ketonaemia, ketonuria, consider T1DM, insulin administration and referral to an endocrinology service. 
**Do not combine GLP1-RA and DPP4i therapy 
***Medications which typically result in weight gain. 
****Consider rationalising oral antidiabetic medication, (e.g. < 3) when commencing insulin, and referral to endocrinology service if not 
already under review 
~ Certain Combination treatments are more costly than others and healthcare systems may dictate which combinations are possible based 
on monetary resources. 
Shared Decision making between the patient and healthcare practitioner is required to agree on treatment, ensuring an individual care 
plan. The patient must be informed of the potential side-effects of medication.  
DPP4i=DPP-4 inhibitor; GLP-1 RA= GLP-1 receptor agonist; SGLT2-i, SGLT2 inhibitor; TZD, thiazolidinedione 
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